Lantern Pharma Launches AI Module to Revolutionize Cancer Treatment

Lantern Pharma (NASDAQ: LTRN), a pioneer in AI-driven oncology drug development, has unveiled a groundbreaking AI-powered module within its RADR(R) platform. This innovative tool is designed to predict the effectiveness of combination therapies that include DNA-damaging agents (DDAs) and DNA damage response inhibitors (DDRis), based on a comprehensive analysis of 221 clinical trials. The module promises to revolutionize cancer treatment by enabling biomarker-guided regimen designs, potentially slashing development time and costs by up to one-third. Notably, Lantern Pharma's platform has already guided the design of an FDA-cleared Phase 1B/2 trial for triple-negative breast cancer, combining LP-184 and olaparib. The company is now looking to expand the reach of this technology through licensing and commercialization across various oncology indications.

For those interested in delving deeper into this development, the full press release is available at https://ibn.fm/NVQqv. Lantern Pharma's RADR(R) platform stands out by leveraging over 200 billion oncology-focused data points and more than 200 advanced machine learning algorithms to address real-world challenges in oncology drug development. This approach has enabled the company to advance drug programs from initial AI insights to first-in-human clinical trials in just 2-3 years, at an average cost of $2.5 million per program, showcasing the transformative potential of AI in accelerating drug discovery and development.